Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LEM-mR203 SARS-CoV-2 Booster Vaccine
NCT06032000Phase 1Completed
- Sponsor
- Lemonex Inc.
- Start
- Nov 2023
- Primary completion
- Mar 2025
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing LEM-mR203 with Placebo (2 arms). Primary endpoint: Safety and Reactogenicity Assessment at 12 months. Started Nov 2023; status: completed.
02
Drugs
LEM-mR203
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06032000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06032000.